Company: LIMN
Filing Date: 2025-01-15
Form Type: CORRESP
Source: 0001104659-25-003831
Chunk: 0

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-15
Form: CORRESP
Chunk 0
---
January 15, 2025

Tamika Sheppard

Tim Buchmiller

Division of Corporation Finance

Office of Life Sciences

United States Securities and Exchange Commission

11 F Street, NE

Washington, D.C. 20549-3561

| Re: | Iris Parent Holding Corp.                                             
 Post- Effective Amendment No. 1 to Registration Statement on Form S-4 
 Filed November 8, 2024                                                |
|:----|:----------------------------------------------------------------------|
|     | File No. 333-275409                                                   |

Ladies and Gentlemen:

This letter sets forth the
response of Iris Parent Holding Corp. (the “Company”) to the comments of the Staff (the “Staff”) of the Securities
and Exchange Commission (the “Commission”) set forth in your letter, dated December 5, 2024, with respect to the Company’s
Post-Effective Amendment No. 1 to Registration Statement on Form S-4, filed with the Commission on November 8, 2024 (the
“Registration Statement”).

Concurrent with the submission
of this letter, we are filing an Post-Effective Amendment No. 2 to the Registration Statement (the “Form S-4”) in
response to the Staff’s comments. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto
in the Registration Statement. For your convenience, the Staff’s comment is reprinted in bold below, followed by the Company’s
response thereto.

Post-Effective Amendment No. 1 to Registration Statement on Form S-4

Cover Page

1. We note your revised disclosure that, after the completion of the Business Combination, Chris Kim will be deemed to beneficially own approximately 32.7% of the outstanding voting power of ParentCo Common Stock, assuming no redemptions (or 33.0% assuming maximum redemptions), and that ParentCo will be a “controlled company” within the meaning of the Nasdaq rules and could elect to take advantage of certain “controlled company” exemptions. Given the revised disclosure regarding the beneficial ownership percentages, please tell us why you continue to disclose that ParentCo will be a “controlled company” after the completion of the Business Combination and could elect to take advantage of certain “controlled company” exemptions, or revise your disclosure as appropriate.

:

In response to the
Staff’s comment, the Company has revised the disclosure on the inside front cover page, in the letter to Iris Acquisition
Corp’s stockholders